Obstetrics & Gynecology · Endocrinology · 4 h ago
Secondary analysis finds early metformin favored for gestational diabetes outcomes
A secondary analysis of a double-masked, placebo-controlled randomized trial involving 526 pregnancies with gestational diabetes found that early metformin favored a composite of insulin initiation and fasting hyperglycemia. The results were statistically significant, with the largest treatment separation for insulin initiation.
- Secondary analysis included 526 pregnancies with gestational diabetes.
- Metformin favored the combined glycemic outcome over placebo.
- Largest separation was observed for insulin initiation.
- Findings may inform future trial endpoint design.
This secondary analysis evaluated 526 pregnancies with gestational diabetes from a double-masked, placebo-controlled randomized trial conducted at two hospitals in Ireland between 2017 and 2022. Participants received metformin, up to 2,500 mg, or matching placebo alongside usual care. Researchers used generalized pairwise comparisons to assess insulin initiation and fasting hyperglycemia at gestational weeks 32 and 38, both in a prioritized hierarchy and in overall summaries.
The prioritized analysis favored metformin over placebo (win ratio, 1.46; 95% CI, 1.13-1.89; P=.004). The largest separation was for insulin initiation (win ratio, 1.68; 95% CI, 1.19-2.38; P=.003). Overall nonprioritized results also favored metformin (win ratio, 1.53; 95% CI, 1.16-2.01; P=.002), with similar findings using prespecified clinical weights.
The authors say these analyses complement the original trial’s primary analysis and may inform endpoint design in future trials. This is a secondary analysis, and the supplied report does not provide absolute event rates. The findings do not establish a change in clinical practice; interpretation should be considered alongside the original trial results.
In practice
For pregnant people with gestational diabetes, this secondary analysis of a placebo-controlled randomized trial found that early metformin, added to usual care, favored a composite of insulin initiation and fasting hyperglycemia over placebo; the largest separation was for insulin initiation. These results provide additional analysis of trial outcomes, not evidence of a new guideline or approval. Because this is a secondary analysis and absolute event rates are not reported in the supplied abstract, it does not by itself justify changing treatment practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
JAMA Network Open: Early Metformin Initiation and Glycemic Outcomes in Gestational Diabetes ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.